Jono Misato, Kinehara Yuhei, Utsu Yoshihiko, Tamura Yoshiro, Koseto Masahiro, Murakami Teruaki, Uota Akifumi, Ninomiya Ryusuke, Komo Satoshi, Sumitani Satoru, Sato Bunzo, Kasayama Soji, Tachibana Isao
Department of Medicine, Nippon Life Hospital, Japan.
Intern Med. 2020 Feb 15;59(4):569-572. doi: 10.2169/internalmedicine.3782-19. Epub 2019 Oct 31.
The patient was a 73-year-old woman with lung adenocarcinoma and systemic lupus erythematosus (SLE) who was treated with pembrolizumab. After six cycles of pembrolizumab, she developed symptoms suggestive of neuropsychiatric SLE, such as resting tremor, confusional state, depression, mood disorder, and anxiety disorder. In addition, her cerebrospinal fluid level of interleukin-6 was elevated. Her symptoms resolved one month after the discontinuation of pembrolizumab. This is the first report of neuropsychiatric symptoms in a patient with lung cancer and SLE on immune checkpoint blockade therapy.
该患者为一名73岁女性，患有肺腺癌和系统性红斑狼疮（SLE），接受了派姆单抗治疗。在接受六个周期的派姆单抗治疗后，她出现了提示神经精神性SLE的症状，如静止性震颤、意识模糊状态、抑郁、情绪障碍和焦虑症。此外，她脑脊液中的白细胞介素-6水平升高。在停用派姆单抗一个月后，她的症状得到缓解。这是首例关于肺癌合并SLE患者在接受免疫检查点阻断治疗后出现神经精神症状的报告。
